292 related articles for article (PubMed ID: 33954073)
1. Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes.
Hussain M; Elahi A; Iqbal J; Bilal Ghafoor M; Rehman H; Akhtar S
Cureus; 2021 Apr; 13(4):e14268. PubMed ID: 33954073
[TBL] [Abstract][Full Text] [Related]
2. Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As Add On Therapy In Type 2 Diabetic Patients.
Hussain M; Atif M; Babar M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(4):593-597. PubMed ID: 35124914
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience.
Islam L; Jose D; Alkhalifah M; Blaibel D; Chandrabalan V; Pappachan JM
World J Diabetes; 2024 Mar; 15(3):463-474. PubMed ID: 38591092
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes.
Hussain M; Elahi A; Hussain A; Iqbal J; Akhtar L; Majid A
J Diabetes Res; 2021; 2021():9973862. PubMed ID: 34239940
[TBL] [Abstract][Full Text] [Related]
5. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
7. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
Yang AY; Chen HC
Int J Clin Pharm; 2021 Aug; 43(4):1015-1023. PubMed ID: 33258006
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
Bhosle D; Indurkar S; Quadri U; Chandekar B
J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
[TBL] [Abstract][Full Text] [Related]
10. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
Yang AY; Chen HC
J Diabetes Res; 2022; 2022():2420857. PubMed ID: 35656359
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
[TBL] [Abstract][Full Text] [Related]
13. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
Babar M; Hussain M; Ahmad M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
15. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
[TBL] [Abstract][Full Text] [Related]
16. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
18. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India.
Fatima Z; Atal S; Joshi R; Sadasivam B
Cureus; 2022 Feb; 14(2):e22141. PubMed ID: 35308676
[TBL] [Abstract][Full Text] [Related]
19. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
20. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
Huang CH; Huang YY; Hsu BR
Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
